摘要
目的探讨术前新辅助化疗联合洛铂术中腹腔灌注化疗对晚期卵巢癌患者血清血管内皮生长因子(VEGF)、人附睾蛋白4(HE4)水平及预后的影响。方法选取我院自2014年6月~2016年7月收治的80例晚期卵巢癌患者,按随机数字表法分为两组,各40例。观察组实施术前新辅助化疗+肿瘤细胞减灭术+洛铂术中腹腔灌注化疗+术后TP方案化疗,对照组实施常规肿瘤细胞减灭术+术后TP方案化疗,比较两组手术情况、短期疗效、血清VEGF与HE4水平变化情况,并随访1、3年生存率。结果观察组的手术时间、术中出血量、腹水量及住院时间均少于对照组(P<0.05);观察组临床总有效率为80.00%,高于对照组的57.50%(P<0.05);治疗后,观察组血清VEGF、HE4水平均较治疗前降低且低于对照组(P<0.05);观察组3年生存率高于对照组(P<0.05)。结论术前新辅助化疗联合洛铂术中腹腔灌注化疗可明显缩短手术时间、减少术中出血量,提升晚期卵巢癌患者短期疗效,且有利于下调血清VEGF、HE4水平,改善预后。
Objective To investigate the effect of preoperative neoadjuvant chemotherapy combined with lobaplatin intraperitoneal chemotherapy on serum vascular endothelial growth factor(VEGF)and human epididymis protein 4(HE4)levels and prognosis in patients with advanced ovarian cancer.Methods Eighty patients with advanced ovarian cancer admitted to our hospital from June 2014 to July 2016 were randomLy divided into two groups,with 40 cases in each group.The observation group underwent preoperative neoadjuvant chemotherapy+cytoreductive surgery+lobaplatin intraperitoneal infusion chemotherapy and postoperative TP regimen,and the control group underwent routine cytoreductive surgery+postoperative TP regimen.The surgical condition,short-term efficacy,serum VEGF and HE4 levels between two groups were compared.And one-year and three-year survival rate was followed up.Results The operation time,intraoperative blood loss,ascites volume and hospitalization time of the observation group were less than those of the control group(P<0.05).The total effective rate of the observation group was 80.00%,which was higher than that(57.50%)of the control group(P<0.05).Serum VEGF and HE4 levels in the observation group after treatment were lower than those before treatment and those in the control group(P<0.05).The three-year survival rate of the observation group was higher than that in the control group(P<0.05).Conclusion Preoperative neoadjuvant chemotherapy combined with lobaplatin intraperitoneal infusion chemotherapy can significantly shorten the operation time,reduce the amount of intraoperative blood loss.It also can improve the short-term efficacy of patients with advanced ovarian cancer,help to down-regulate serum VEGF,HE4 levels and improve prognosis.
作者
闫喜秋
YAN Xiqiu(Department of Reproductive Medicine,Jiamusi Maternal and Child Health Hospital in Heilongjiang Province,Jiamusi 154002,China)
出处
《中国现代医生》
2020年第10期4-7,共4页
China Modern Doctor
关键词
新辅助化疗
腹腔灌注化疗
晚期
卵巢癌
VEGF
HE4
Neoadjuvant chemotherapy
Intraperitoneal chemotherapy
Advanced
Ovarian cancer
VEGF
HE4
